Satraplatin 60215 123(12): 5298–5309

123(12): 5298–5309

InChi: InChI=1S/C17H18ClN7O

2017 May 15

11a-dimethyl-7-oxo-hexadecahydro-1H-cyclopenta[a]phenanthren-1-yl 2-[2-(2-{2-[(2S)-2-[(2S

the foot swelling degree of the arthritis part is also obviously slowed down

Satraplatin 60215 123(12): 5298–5309Satraplatin, also known as JM216 and BMS182751, is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. It has not yet received approval from the U. S. Food and Drug Administration. First mentioned in the medical literature in 1993, satraplatin is the first orally active platinum based chemotherapeutic drug; other available platinum